Taking time to get a second opinion on breast cancer treatment did not significantly alter the time to treatment, which still ...

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that an abstract on abenacianine for injection (VGT-309) will be featured at the 2025 ...

AppLovin (NasdaqGS:APP) recently reported strong first-quarter results with significant sales and net income increases, alongside issuing positive guidance for the second quarter, which seems to align ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

After further evaluation, she was diagnosed with cholangiocarcinoma, or bile duct cancer, a rare and aggressive cancer that ...

Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. The market awaits NeoGenomics's ...

Delcath Systems’ strong Q1 2025 performance underscores its momentum in expanding HEPZATO’s adoption across the U.S. and advancing its clinical trial pipeline. With a positive cash flow, no debt, and ...

Analysts have recently evaluated Veracyte and provided 12-month price targets. The average target is $44.71, accompanied by a ...

A new national survey has revealed a surprising gap in public health knowledge: many Americans don’t realize that drinking ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Guardant Health exceeds Q1 expectations, boosts growth outlook, and gains from favorable pricing and approvals. Read more ...